Lucid Diagnostics Inc.
LUCD · XNASCIK 1799011fmd_1JZ7773W63SZ9S7C3WT17KSXM2Manufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 25 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | 1 | 0 | 2 | 4 | 5 |
| Cost of revenue | – | 1 | 100 | – | 7 | 7 |
| Gross profit | – | 1 | 0 | – | (3) | (2) |
| Research and development | 5 | 9 | 11 | 7 | 6 | 6 |
| Selling, general and administrative | 0 | 0 | 40 | 36 | 37 | 42 |
| Total operating expenses | 8 | 28 | 57 | 51 | 50 | – |
| Operating income | (8) | (27) | (56) | (48) | (46) | (50) |
| Interest expense | – | 1 | 0 | 0 | 0 | 0 |
| Interest and investment income | – | – | – | – | 0 | 0 |
| Other non-operating income (expense) | – | (1) | 0 | (4) | 1 | (8) |
| Income before taxes | (8) | (28) | (56) | (53) | (46) | (58) |
| Income tax expense | – | – | – | – | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (46) | (58) |
| Net income | (8) | (28) | (56) | (53) | (46) | (58) |
| Net income to common shareholders | – | – | – | (53) | (53) | (71) |